

mondoBIOTECH holding AG (SIX: RARE): Exclusive engagement with financial services firm WR Hambrecht + Co., LLC

Send to a friend

!

Print

!

RSS Feed

!

Published online 23 April 2010

STANS - mondoBIOTECH holding AG (SIX: RARE) announces exclusive engagement with prominent Silicon Valley financial services firm WR Hambrecht + Co.

Mondobiotech CEO Fabio Cavalli and President of WR Hambrecht + Co. Elizabeth Hambrecht announce today an agreement establishing Hambrecht as the exclusive placement agent for Mondobiotech's securities. The relationship brings the innovative and extensive experience of WR Hambrecht in Silicon Valley financing to the innovative Mondobiotech mission and methods discovering and making available new therapies for the treatment of rare diseases.

WR Hambrecht + Co. will advise and assist the company in the preparation of strategies and documentation as well as the identification of and contracting with prospective purchasers of Mondobiotech securities.

WR Hambrecht + Co. has assigned a team of analysts, market strategists, and senior executives, led by Elizabeth Hambrecht herself to work with officers and board members of mondoBIOTECH holding AG to accomplish these tasks and implement the strategic placements contemplated by the agreement.

This agreement is another step in the realization of the mission of Mondobiotech to support and to engage communities of patients with rare diseases, their families, and their physicians. It is expected that the engagement of WR Hambrecht + Co. should provide for the material expansion of Mondobiotech's therapeutic pipelines for the direct benefit of people suffering from rare diseases.

Founded in 1998 by William R. Hambrecht, WR Hambrecht + Co. is a financial services firm committed to using technology and auction processes to provide open and fair access to financial markets for all its clients. The firm's impartial auctions, which allow the market to determine pricing and allocation, are dramatically changing the financial services landscape. WR Hambrecht + Co. is headquartered in San Francisco with offices in New York and Philadelphia. <http://www.wrhambrecht.com/>

About Mondobiotech

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent, internet-based biotech research company, discovers drugs for patients suffering from rare and neglected diseases. Mondobiotech has built a continuously growing global community of biologists, biochemists, physicians,

and patient advocacy organizations who share their passion and skills with Mondobiotech. Together with Mondobiotech, this community is searching for treatments for rare and neglected diseases.

For further information please contact:
mondoBIOTECH holding AG

Das Kloster

Mürgstrasse 18

CH-6370 Stans

Tel.: +41 (0) 840 200 010

Fax: +41 (0) 840 200 011

press@mondobiotech.com
www.mondobiotech.com

Disclaimer

The foregoing release may contain forward-looking statements. The words "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. mondoBIOTECH holding AG may not achieve the plans, intentions or expectations disclosed in its forward-looking statements and prospective investors should not place reliance on mondoBIOTECH holding AG's forward looking statements. There can be no assurance that results of the activities and results of operations will not differ materially from the expectations. Forward-looking statements are subject to inherent risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by or underlying the forward looking statements. mondoBIOTECH holding AG is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Source: mondoBIOTECH